WHO Approves First Mpox Diagnostic Test for Emergency Use

WHO Approves First Mpox Diagnostic Test for Emergency Use

• The World Health Organization (WHO) has approved the first emergency use diagnostic test for mpox, previously known as monkeypox.
• The test, named Alinity m MPXV, was developed by Abbott Molecular Inc.
• It has been included in WHO’s Emergency Use Listing (EUL).
• This approval will improve the ability of impacted areas to swiftly identify the virus.
• It aims to help control the spread of mpox during ongoing global outbreaks.

Urgent Need for Mpox Testing

• The mpox virus remains a significant health challenge, particularly in Africa.
• In 2024, more than 30,000 suspected cases of mpox have been reported.
• The Democratic Republic of Congo (DRC), Burundi, and Nigeria are the most affected countries.
• Testing capacities in these regions are severely limited.
• Only 37% of suspected cases in the DRC have been confirmed through testing.

Importance of Early Diagnosis

• Early diagnosis is crucial for effectively managing mpox outbreaks.
• Timely identification enables prompt medical intervention, which helps reduce transmission rates.
• Ensuring that patients obtain timely and necessary care is crucial. In this regard, the World Health Organization emphasized the importance of the Alinity m MPXV test.
• The test effectively identifies mpox DNA present in human skin lesions through real-time PCR testing.
• It is designed for laboratory use by trained personnel, providing a reliable method to confirm suspected cases.

Expanding Access to Diagnostics

• One of the main objectives of the WHO’s approval is to enhance access to mpox diagnostics in underserved regions.
• Yukiko Nakatani, WHO’s Assistant Director-General for Access to Medicines and Health Products, emphasized that this approval represents a significant milestone in global health initiatives.
• This development is especially important for countries that do not have the resources to create their own diagnostic tools.
• The diagnostic test will now be accessible for purchase by these nations via international procurement agencies.

WHO’s Emergency Use Listing (EUL) Process

• The WHO’s Emergency Use Listing (EUL) process accelerates the availability of life-saving health products during public health emergencies.
• It assesses the quality, safety, and performance of diagnostic tools, vaccines, and treatments, ensuring they meet international standards.
• The Alinity m MPXV test was the first mpox diagnostic to receive EUL approval.
• In August 2024, WHO urged more manufacturers to submit their tests for EUL approval to address the increasing global demand for mpox diagnostics.
• Currently, three additional diagnostic tools are under review, and WHO is engaging with other manufacturers for potential submissions.

Impact on Africa and Global Health

• The mpox outbreak in Africa is still a significant concern.
• Delayed confirmations of cases are contributing to the spread of the virus.
• Increasing diagnostic capacity in regions where the virus is prevalent is crucial for controlling the epidemic.
• The Alinity m MPXV test will play a vital role in addressing this diagnostic gap.
• This test enables faster detection of mpox in areas with limited laboratory infrastructure.
• Improved detection will facilitate more effective public health interventions.

Future Developments

• The World Health Organization (WHO) is collaborating with manufacturers to broaden the availability of mpox diagnostic tools.
• By approving additional tests, WHO aims to equip healthcare systems with necessary resources to contain the virus.
• The Emergency Use Listing (EUL) approval for the Alinity m MPXV test will remain effective as long as mpox is classified as a Public Health Emergency of International Concern (PHEIC).
• This highlights the urgency of sustaining global efforts to control the mpox virus.

Important questions

1. What is the name of the first emergency use diagnostic test approved by the WHO for mpox?
2. How does the Alinity m MPXV test help in managing mpox outbreaks?
3. What are some of the countries most affected by mpox, according to the article?
4. How does the WHO’s Emergency Use Listing (EUL) process benefit public health emergencies?
5. What impact does the Alinity m MPXV test have on regions with limited laboratory infrastructure?

Conclusion

The World Health Organization’s approval of the Alinity m MPXV diagnostic test for emergency use represents a significant advancement in the fight against mpox, particularly in regions like Africa where testing capabilities are limited. With over 30,000 suspected cases reported in 2024 and a low confirmation rate in the Democratic Republic of Congo, this test is critical for enabling timely diagnoses and effective public health responses. The WHO’s Emergency Use Listing process underscores the importance of making reliable diagnostic tools accessible to underserved nations, and as the situation evolves, continued collaboration with manufacturers is essential to expand the range of diagnostics available, ultimately aiding in the control of mpox outbreaks globally.

Download Online Mock Test Mobile APP

• Join Official Telegram Channel
• Join Official Whatsapp Group

Recommended PDF’s for 2024:

• Computer Capsule 2024 : Download PDF
• Banking Awareness (Theory+MCQ’s) Complete PDF : Download Now
• Get FREE Study Materials & PDFs for IBPS , RBI, SBI, LIC AAO , LIC Assistant, NIACL & Other Exams Over the mail and Whatsapp